logo
Investing in these 3 chemical sector stocks can give good returns now as sector is reviving

Investing in these 3 chemical sector stocks can give good returns now as sector is reviving

Time of India02-06-2025

After a lull of about three years, India's chemicals sector now appears poised for an upgrade. If you are looking for a contrarian
investment strategy
, then you might want to take a small exposure to this sector. Here's why.
On a rebound
The sector saw a marginal but noticeable improvement in performance during the January–March 2025 quarter. While much of the gain can be attributed to the low base effect, analysts remain optimistic. Of the 32 companies tracked by Reuters-Refinitiv (with estimates from at least two analysts), 19—or 59.3%—beat net
profit expectations
for the quarter.
Anuj Jain, Co-founder of Green Portfolio PMS, says the March quarter results signal the beginning of an upcycle in the chemicals industry after a pause of nearly 2–3 years. Though valuations remain high for several large-cap stocks in the sector, many mid- and small-cap companies are still available at attractive valuations.
A bleak past
The chemicals sector has faced persistent headwinds over the past few quarters due to muted demand, weak realisations amid pricing pressures, inventory destocking in the agrochemicals segment, and heightened competition from China. Data compiled from the Reuters-Refinitiv database for 139 chemical companies with a market cap of more than Rs.100 crore shows dismal aggregate revenue growth of just 2% and 3.4% in the June and September quarters of 2024-25, on a year-on-year basis.
Nearly 54% of these companies underperformed the Nifty 500 index over the last year, while 66% lagged the broader market benchmark in 2025 year-to-date.
Live Events
Brokers upbeat, but wary
A pick-up in domestic demand for RACs (room air conditioners) and the sheer rise in demand for gas used in refrigeration and air conditioning is expected to bode well for the sector. While a B&K Securities report highlights that the weakening of competition from within the European Union will open up export opportunities for Indian companies, it also cautions against the continued threat of strong competition from China.
On the other hand, a gradual recovery is expected in the agrochemicals segment, supported by the rising demand for newer, innovative products and biological alternatives. A Motilal Oswal report released in March 2025 notes that prices in the global crop protection industry are likely to bottom out in 2025 across all key regions and product segments, paving the way for a more stable growth trajectory ahead.
The B&K Securities report notes that a sustained recovery in demand from the EU27 block is crucial to boosting the export growth potential of the Indian chemicals industry. It adds that with inventory de-stocking now largely complete in European markets, both demand and volumes are expected to drive growth going forward.
Challenges
The US trade tariffs, low-cost dumping by Chinese manufacturers, and weak demand in Europe remain some of the major concerns for the sector. An April 2025 Kotak Securities report expresses hope for a decent recovery over 2024–25 and 2026–27. However, in the event of a prolonged tariff war, it cautions that there could be more substantial downside risk to these expectations. Here are three companies worth considering for a small exposure. These firms have reported double-digit growth in net earnings for the March 2025 quarter and enjoy the highest level of analyst coverage within the sector.
SRF
Q4 revenue and net profit beat estimates by 7.4% and 9.3%.
Strong performance in specialty chemicals, refrigerant gases, and packaging films.
2025-26 revenue guidance at 20% growth.
Elara Capital maintains an 'accumulate' rating, expecting gains from recovering demand.
Navin Fluorine
Q4 revenue and EBITDA beat estimates by 2.4% and 7.9%.
CDMO (Contract Development and Manufacturing Organisation) and high-performance products drove growth.
Refrigerant gas demand and better pricing supported performance.
Management targets ~25% EBITDA margin in 2025-26.
Prabhudas Lilladher sees strong long-term growth potential.
UPL
Q4 revenue and EBITDA beat estimates by 3.6% and 9.9%.
Growth is driven by strong volumes, and inventory normalisation.
2025-26 revenue growth guided at 4-8%, led by volumes.
Recovery in key markets and new products to aid growth.
Antique sees balance sheet improving and growth momentum continuing.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Top researcher who quit OpenAI to join Meta calls out Sam Altman for ‘fake news'
Top researcher who quit OpenAI to join Meta calls out Sam Altman for ‘fake news'

Hindustan Times

time13 minutes ago

  • Hindustan Times

Top researcher who quit OpenAI to join Meta calls out Sam Altman for ‘fake news'

Mark Zuckerberg has poached three of OpenAI's top researchers for Meta – but contrary to Sam Altman's claims, they did not get $100 million as a sign-on bonus. Lucas Beyer, a former OpenAI researcher, dismissed Altman's claims that Meta paid $100 million to the OpenAI employees joining its superintelligence team. Mark Zuckerberg (L) and Sam Altman (R) are locked in a race over AI.(AP, Reuters) Beyer took to social media to set the record straight after OpenAI CEO Sam Altman claimed that Meta offered his employees bonuses of $100 million to recruit them. According to a Wall Street Journal report, the top OpenAI researchers who quit the ChatGPT-maker are Lucas Beyer, Alexander Kolesnikov, and Xiaohua Zhai. All of them worked out of OpenAI's Zurich office. What did Sam Altman say about $100 million bonus? During an appearance on the Uncapped podcast in mid June, OpenAI's Altman claimed that Meta 'started making giant offers to a lot of people on our team' like '$100 million signing bonuses, more than that (in) compensation per year.' And how did Lucas Beyer refute this claim? Lucas Beyer, a former Google employee who had been with OpenAI since 2024, recently quit the AI firm to join Meta. In a post shared on X, he refuted Sam Altman's claims that he and other top researchers were paid nine figure signing bonuses. 'Hey all, couple quick notes: 1) yes, we will be joining Meta. 2) no, we did not get 100M sign-on, that's fake news,' Beyer posted on X. In the comments section, he took a direct dig at Altman's claims - 'Thank God Sam let me know I've been lowballed,' Beyer wrote in a tongue-in-cheek response to an X user. Why has Meta ramped up hiring? According to Reuters, Meta, once recognized as a leader in open-source AI models, has suffered from staff departures and has postponed the launches of new open-source AI models that could rival competitors like Google, China's DeepSeek and OpenAI.

Torrent Pharma shares in focus after Rs 11,900 crore JB Chemicals acquisition
Torrent Pharma shares in focus after Rs 11,900 crore JB Chemicals acquisition

Economic Times

time14 minutes ago

  • Economic Times

Torrent Pharma shares in focus after Rs 11,900 crore JB Chemicals acquisition

Shares of Torrent Pharmaceuticals are likely to be in the spotlight on Monday, June 30, after the company announced a major acquisition worth Rs 11,917 crore to acquire a controlling stake in J.B. Chemicals & Pharmaceuticals Ltd, another player in the pharmaceutical sector. ADVERTISEMENT In a board meeting held on June 29, Torrent Pharma approved a multi-step transaction to acquire a majority stake in JB Chemicals. The acquisition comprises the following: Share Purchase Agreement (SPA): Torrent will acquire 7.44 crore equity shares, representing 46.39% of JB Chemicals' fully diluted equity share capital, from its promoter, Tau Investment Holdings Pte Ltd, at Rs 1,600 per share, amounting to approximately Rs 11,917 crore, subject to shareholder and regulatory approvals. Potential Employee Acquisition: Torrent may further acquire up to 44.99 lakh equity shares (2.80%) from certain employees at a price not exceeding Rs 1,600 per share, through employee stock Offer: Torrent has also proposed an open offer to public shareholders to acquire up to 4.17 crore shares (26.00%) of the expanded capital at Rs 1,639.18 per share, in accordance with SEBI's Takeover Torrent will gain promoter status and a controlling interest in JB Chemicals, positioning it to expand its product offerings and leverage synergies between the two firms. ADVERTISEMENT JB Chemicals, incorporated in 1976, is a publicly listed company with a consolidated turnover of Rs 3,918 crore and a net worth of Rs 3,433 crore as of March 31, 2025. The company has consistently maintained strong financial performance over the last three proposed acquisition is subject to approvals from the Competition Commission of India (CCI), shareholders, and other statutory bodies. Torrent Pharma anticipates completing the deal within six months. ADVERTISEMENT On Friday, shares of Torrent Pharmaceuticals closed 3.7% higher at Rs 3,344.40 on BSE. Also read: Nifty ready to scale new highs on bullish mood: Analysts (Disclaimer: Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)

Star Entertainments Queens Wharf stake exit deal collapses
Star Entertainments Queens Wharf stake exit deal collapses

Mint

time14 minutes ago

  • Mint

Star Entertainments Queens Wharf stake exit deal collapses

(Adds shares in paragraph 4, background in paragraphs 5-8, additional details in paragraph 10) June 30 (Reuters) - Australia's Star Entertainment said it had received a notice from Hong Kong's Far East Consortium International and Chow Tai Fook Enterprises to terminate the deal to sell its 50% stake in its Queen's Wharf project in Brisbane. The termination is set to take effect five business days from June 30, unless withdrawn earlier. The March 7 agreement outlined the casino operator's planned exit from its equity interest in Destination Brisbane Consortium (DBC), but the parties had not resolved outstanding key commercial issues of the deal as of this morning, Star said in a statement on Monday. Shares of Star were, however, up 1.7% at A$0.147, as of 0104 GMT. The casino and hotel complex was developed for A$3.6 billion ($2.35 billion), Star's website says. For years, Star and Blackstone-owned larger rival Crown Resorts have faced multiple inquiries into anti-money laundering rule violations and subsequent legal actions. Had the deal gone through, Far East Consortium and Chow Tai Fook Enterprises were set to become the sole owner of the Brisbane venture, which has luxury hotels and restaurants and other amenities. Star was, in turn, set to take on the investors' 66.67% stake in a Gold Coast project in Queensland. In a separate statement, property developer Far East Consortium said that Star must repay A$10 million within 30 days of termination, failing which it must transfer its 33.3% stake in Tower 1 (Dorsett) to the Hong Kong parties. "Despite the receipt of this notice, The Star remains willing to continue negotiations with the Joint Venture Partners to give effect to the DBC transaction," Star added. Star Entertainment did not immediately respond to a Reuters email seeking confirmation of the repayment details. ($1 = 1.5314 Australian dollars) (Reporting by Shivangi Lahiri in Bengaluru; Editing by Rashmi Aich)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store